Percutaneous coronary intervention for coronary artery stenosis
Conditions
Interventions
Trade Name: Aggrastat
Product Name: Aggrastat
Product Code: Aggrastat
Pharmaceutical Form: Solution for infusion
Sponsors
Sheffield Teaching Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Aged 18 years or over Patients with acute coronary syndromes scheduled for urgent or emergency coronary angiography Patients scheduled for high-risk elective PCI Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Increased risk of bleeding sufficient to contra-indicate the use of GPIIb/IIIa antagonists, according to British National Formulary guidance for the use of these drugs: Active internal bleeding; majory surgery, intracranial or intraspinal surgery or trauma within the last 2 month; stroke within the last 2 years; intracranial neoplasm, arteriovenous malformation or aneurysm; severe uncontrolled hypertension; haemorrhagic diasthesis, thrombocytopenia or INR > 2.0; vasculitis; hypertensive or untreated proliferative diabetic retinopathy. Currently receiving abciximab or eptifibatide (increased risk of bleeding due to interaction). Creatinine > 300 umol/L (risk of drug accumulation) Breast feeding (risk of toxicity, listed as contraindication in the BNF)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To study the safety and feasibility of dose-adjusted tirofiban in patients undergoing percutaneous coronary intervention using a whole blood microaggregation assay;Secondary Objective: ;Primary end point(s): Not specified - see protocol | — |
Countries
United Kingdom
Outcome results
None listed